title: Concentration of anti-D antibodies in Rh(D) alloimmunized pregnant women, as a predictor of anemia and/or hyperbilirubinemia in their newborn infants.
abstract: OBJECTIVE
  To define a simple, safe and reliable program for the monitoring of anti-D alloimmunized pregnancies by analysis of the covariation between antenatal values of the titer and the concentration of anti-D antibodies in maternal serum, the deltaOD(450 nm) in amniotic fluid samples, and the levels of B-hemoglobin and S-bilirubin in the newborns at birth.
  
  
  METHODS
  Ninety-three Rh(D) negative women with anti-D antibody titers > or = 16 who, after the completed 34th gestational week, gave birth to Rh(D) positive babies with a positive direct antiglobulin test.
  
  
  METHODS
  The titers and the concentrations of anti-D antibodies in maternal serum were determined by standard procedures every second week from the 25th week of gestation. In 47 of the 93 women, deltaOD(450 nm) in amniotic fluid was determined at least once. All antenatal values used in the study were determined within 14 days before delivery.
  
  
  CONCLUSIONS
  Maternal serum antibody titers < or = 32 or > or = 1000 could in themselves well predict unaffected and affected newborns. Antibody titers between 64 and 512 could not accurately predict newborns with or without hemolytic disease. As a complementary monitoring test, determination of the deltaOD(450 nm) was found to be less accurate when compared to determination of the concentration of anti-D antibodies. In order to monitor Rh(D) alloimmunized pregnancies, determination of the concentration of anti-D antibodies may possibly replace determination of deltaOD(450 nm).
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital, Linköping, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Gottvall
authors.forename: J O
authors.initials: JO
authors.lastname: Hildén
mesh_terms: D000653:Amniotic Fluid / Q000276:immunology*; D000745:Anemia, Hemolytic, Congenital / Q000276:immunology*; D001663:Bilirubin / Q000032:analysis; D004899:Erythroblastosis, Fetal / Q000276:immunology*; D005260:Female; D006801:Humans; D006932:Hyperbilirubinemia / Q000276:immunology*; D007231:Infant, Newborn; D007518:Isoantibodies / Q000032:analysis / Q000276:immunology; D011237:Predictive Value of Tests; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology*; D011296:Prenatal Diagnosis; D012203:Rh Isoimmunization; D012204:Rh-Hr Blood-Group System / Q000276:immunology*
chemical_list: D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System; C026410:Rho(D) antigen; D001663:Bilirubin